# US 8,278,348 B2 · Chondropsin-class antitumor V-atpase inhibitor compounds, compositions and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,348 B2
- Document ID: US8278348B2
- Status: Granted
- Kind: B2
- Application number: 12/909,979
- Filed: 2010-10-22
- Published: 2011-02-10
- Granted: 2012-10-02
- Earliest claimed: 2002-07-24
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Inventors: Michael R. Boyd; Kirk R. Gustafson
- Web page: https://patentgrep.com/patent/US8278348B2

## CPC

- C07D 498/08: Bridged systems
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 31/10: Antimycotics
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- C07D 309/06: Radicals substituted by oxygen atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A composition comprising a substantially purified compound of the formula: in combination with at least one additional therapeutic agent, and methods of preventing or treating cancer and a condition treatable by the inhibition of vacuolar-type (H+)-ATPase.

## Claims

### Claim 1

A method of inhibiting vacuolar-type (H+)-ATPase in a patient in need thereof, the method comprising administering to the patient a vacuolar-type (H+)-ATPase-inhibiting effective amount of at least one compound of the formula:
wherein:
R1 is H, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof, wherein R1 is unsubstituted or substituted with one or more substituents, which are the same or different, selected from the group consisting of a halogen, an oxo, OR1a, CO2R1a, and OC(O)R1a, wherein R1a is H, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof;
R2-R8 are the same or different and each is R10, C(O)R10, SO3R10, or SO2R10, wherein R10 is H, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof, wherein R10 is unsubstituted or substituted with one or more substituents, which are the same or different, selected from the group consisting of a halogen, an oxo, OR10a, CO2R10a and OC(O)R10a, wherein R10a is H, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof; and
R9 is a substituent of the formula:
wherein the R9a substituents are the same or different and each is R11, C(O)R11, or SO2R11, wherein R11 is H, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof, wherein R11 is unsubstituted or substituted with one or more substituents, which are the same or different, selected from the group consisting of a halogen, an oxo, OR11a, CO2R11a and OC(O)R11a, wherein R11a is H, a straight-chain or branched C1-30 saturated alkyl, a straight-chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof;
wherein R1a, R10a and R11a are unsubstituted or substituted with one or more substituents selected from the group consisting of a halogen, an oxo, and a hydroxyl; or a pharmaceutically acceptable salt thereof,
whereupon vacuolar-type (H+)-ATPase in the patient is inhibited.

### Claim 2 (depends on 1)

The method of claim 1, wherein:
R1 is H or a straight-chain or branched C1-30 saturated alkyl;
R2-R8 are the same or different and each is R10, wherein R10 is H or a straight-chain or branched C1-30 saturated alkyl; and
the R9a substituents are the same or different and each is R11, wherein R11 is H or a straight-chain or branched C1-30 saturated alkyl;
or a pharmaceutically acceptable salt thereof,
whereupon vacuolar-type (H+)-ATPase in the patient is inhibited.

### Claim 3 (depends on 2)

The method of claim 2, wherein:
R1 is H or a straight-chain or branched C1-6 saturated alkyl;
R2-R8 are the same or different and each is R10, wherein R10 is H or a straight-chain or branched C1-6 saturated alkyl; and
the R9a substituents are the same or different and each is R11, wherein R11 is H or a straight-chain or branched C1-6 saturated alkyl;
or a pharmaceutically acceptable salt thereof,
whereupon vacuolar-type (H+)-ATPase in the patient is inhibited.

### Claim 4 (depends on 1)

The method of claim 1, wherein:
the compound is a compound of the formula:
or a pharmaceutically acceptable salt thereof,
whereupon vacuolar-type (H+)-ATPase in the patient is inhibited.

### Claim 5 (depends on 4)

The method of claim 4, wherein:
the compound is a compound of the formula:
or a pharmaceutically acceptable salt thereof,
whereupon vacuolar-type (H+)-ATPase in the patient is inhibited.

### Claim 6 (depends on 1)

The method of claim 1, wherein the patient is affected by a condition treatable by inhibition of vacuolar-type (H+)-ATPase.

### Claim 7 (depends on 6)

The method of claim 6, wherein the condition is selected from the group consisting of osteoporosis, Alzheimer's disease, glaucoma, fertility, abnormal urinary acidification, abnormal secretion of degradative enzymes, fungal infection and cancer.

### Claim 8 (depends on 6)

The method of claim 6, wherein the vacuolar-type (H+)-ATPase inhibiting-effective amount is effective to inhibit one or more conditions selected from the group consisting of intra-organellar acidification of intracellular organelles, urinary acidification, bone resorption, fertility, drug-resistance of tumor cells, tumor cell proliferation, cellular invasiveness, angiogenesis, and metastasis.

### Claim 9 (depends on 6)

The method of claim 6, wherein the method further comprises administering a vacuolar-type (H+)-ATPase inhibiting-effective amount of at least one additional compound other than a compound of formula (I), which inhibits vacuolar-type (H+)-ATPase, wherein the at least one additional compound is salicylihalamide.
